Human β-defensin-3 inhibits migration of colon cancer cells via downregulation of metastasis-associated 1 family, member 2 expression Corrigendum in /ijo/46/4/1858

Uraki,Satoko; Sugimoto,Kazushi; Shiraki,Katsuya; Tameda,Masahiko; Inagaki,Yuji; Ogura,Suguru; Kasai,Chika; Nojiri,Keiichiro; Yoneda,Misao; Yamamoto,Norihiko; Takei,Yoshiyuki; Nobori,Tsutomu; Ito,Masaaki

doi:10.3892/ijo.2014.2507

Human β-defensin-3 inhibits migration of colon cancer cells via downregulation of metastasis-associated 1 family, member 2 expression

Corrigendum in: /ijo/46/4/1858

Authors:
- Satoko Uraki
- Kazushi Sugimoto
- Katsuya Shiraki
- Masahiko Tameda
- Yuji Inagaki
- Suguru Ogura
- Chika Kasai
- Keiichiro Nojiri
- Misao Yoneda
- Norihiko Yamamoto
- Yoshiyuki Takei
- Tsutomu Nobori
- Masaaki Ito
View Affiliations

Affiliations: First Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan, Department of Gastroenterology, Mie University School of Medicine, Tsu, Japan, Department of Molecular and Laboratory Medicine, Mie University School of Medicine, Tsu, Japan
Published online on: June 20, 2014 https://doi.org/10.3892/ijo.2014.2507
Pages: 1059-1064

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The innate immune system plays an important role as the first line of defense against many types of microbes. Accumulating reports suggest that human β-defensins (hBDs) are expressed by and have certain roles in some cancer cells. In this study, we investigated the roles of hBD-3 in colon cancer cells. The expression of hBD-3 was examined by reverse transcriptase-polymerase chain reaction analysis of colon cancer cell lines and immunohistochemical staining of colon cancer tissues. The effect of hBD-3 on proliferation of colon cancer was assessed using the MTT assay and a real‑time cell analyzer, and the effect of hBD-3 on the migration of colon cancer cells was also examined. The results showed that hBD-3 is not expressed in colon cancer cells but is produced by tumor-infiltrating monocytes. Migration of colon cancer cells was significantly inhibited by hBD-3 in a dose-dependent manner, although proliferation of colon cancer cells was not affected by administration of hBD-3. Moreover, reduced expression of metastasis-associated 1 family, member 2 (MTA2) mRNA in colon cancer cells was associated with exposure to hBD-3. In conclusion, progression of colon cancer was inhibited by hBD-3 in a paracrine fashion. Therefore, hBD-3 may be a potent new agent for treating colon cancer.

View Figures

View References

1	Raj PA and Dentino AR: Current status of defensins and their role in innate and adaptive immunity. FEMS Microbiol Lett. 206:9–18. 2002. View Article : Google Scholar : PubMed/NCBI
2	Ganz T: Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 3:710–720. 2003. View Article : Google Scholar : PubMed/NCBI
3	Yang D, Biragyn A, Hoover DM, Lubkowski J and Oppenheim JJ: Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol. 22:181–215. 2004. View Article : Google Scholar
4	Schutte BC, Mitros JP, Bartlett JA, et al: Discovery of five conserved beta-defensin gene clusters using a computational search strategy. Proc Natl Acad Sci USA. 99:2129–2133. 2002. View Article : Google Scholar : PubMed/NCBI
5	Jia HP, Schutte BC, Schudy A, et al: Discovery of new human beta-defensins using a genomics-based approach. Gene. 263:211–218. 2001. View Article : Google Scholar : PubMed/NCBI
6	Sorensen OE, Thapa DR, Rosenthal A, Liu L, Roberts AA and Ganz T: Differential regulation of beta-defensin expression in human skin by microbial stimuli. J Immunol. 174:4870–4879. 2005. View Article : Google Scholar
7	Zlotnik A and Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity. 12:121–127. 2000. View Article : Google Scholar : PubMed/NCBI
8	Wu Z, Hoover DM, Yang D, et al: Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human beta-defensin 3. Proc Natl Acad Sci USA. 100:8880–8885. 2003. View Article : Google Scholar : PubMed/NCBI
9	Shestakova T, Zhuravel E, Bolgova L, Alekseenko O, Soldatkina M and Pogrebnoy P: Expression of human beta-defensins-1, 2 and 4 mRNA in human lung tumor tissue: a pilot study. Exp Oncol. 30:153–156. 2008.PubMed/NCBI
10	Shestakova T, Zhuravel E, Bolgova L, et al: Immunohistochemical analysis of beta-defensin-2 expression in human lung tumors. Exp Oncol. 32:273–276. 2010.PubMed/NCBI
11	Arimura Y, Ashitani J, Yanagi S, et al: Elevated serum beta-defensins concentrations in patients with lung cancer. Anticancer Res. 24:4051–4057. 2004.PubMed/NCBI
12	Markeeva N, Lisovskiy I, Lyzogubov V, et al: Expression of beta-defensin-2 in human gastric tumors: a pilot study. Exp Oncol. 27:130–135. 2005.PubMed/NCBI
13	Markeeva N, Lysovskiy I, Zhuravel E, et al: Involvement of human beta-defensin-2 in proliferation of transformed cells of human cervix. Exp Oncol. 27:308–313. 2005.PubMed/NCBI
14	Mburu YK, Abe K, Ferris LK, Sarkar SN and Ferris RL: Human beta-defensin 3 promotes NF-kappaB-mediated CCR7 expression and anti-apoptotic signals in squamous cell carcinoma of the head and neck. Carcinogenesis. 32:168–174. 2010. View Article : Google Scholar : PubMed/NCBI
15	Melle C, Ernst G, Schimmel B, et al: Discovery and identification of alpha-defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenterology. 129:66–73. 2005. View Article : Google Scholar : PubMed/NCBI
16	Albrethsen J, Bogebo R, Gammeltoft S, Olsen J, Winther B and Raskov H: Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1–3) in colon cancer serum and tumours: a biomarker study. BMC Cancer. 5:82005.
17	Albrethsen J, Moller CH, Olsen J, Raskov H and Gammeltoft S: Human neutrophil peptides 1, 2 and 3 are biochemical markers for metastatic colorectal cancer. Eur J Cancer. 42:3057–3064. 2006. View Article : Google Scholar : PubMed/NCBI
18	Wang K, Wang JH, Baskaran H, Wang R and Jurevic R: Effect of human beta-defensin-3 on head and neck cancer cell migration using micro-fabricated cell islands. Head Neck Oncol. 4:412012. View Article : Google Scholar : PubMed/NCBI
19	Kawsar HI, Weinberg A, Hirsch SA, et al: Overexpression of human beta-defensin-3 in oral dysplasia: potential role in macrophage trafficking. Oral Oncol. 45:696–702. 2009. View Article : Google Scholar : PubMed/NCBI
20	Winter J, Pantelis A, Reich R, et al: Human beta-defensin-1, -2, and -3 exhibit opposite effects on oral squamous cell carcinoma cell proliferation. Cancer Invest. 29:196–201. 2011. View Article : Google Scholar : PubMed/NCBI
21	Harder J, Bartels J, Christophers E and Schroder JM: Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem. 276:5707–5713. 2001. View Article : Google Scholar : PubMed/NCBI
22	Kawauchi K, Yagihashi A, Tsuji N, et al: Human beta-defensin-3 induction in H. pylori-infected gastric mucosal tissues. World J Gastroenterol. 12:5793–5797. 2006.PubMed/NCBI
23	Fahlgren A, Hammarstrom S, Danielsson A and Hammarstrom ML: beta-Defensin-3 and -4 in intestinal epithelial cells display increased mRNA expression in ulcerative colitis. Clin Exp Immunol. 137:379–385. 2004. View Article : Google Scholar
24	Donald CD, Sun CQ, Lim SD, et al: Cancer-specific loss of beta-defensin 1 in renal and prostatic carcinomas. Lab Invest. 83:501–505. 2003. View Article : Google Scholar : PubMed/NCBI
25	Young AN, de Oliveira Salles PG, Lim SD, et al: Beta defensin-1, parvalbumin, and vimentin: a panel of diagnostic immunohistochemical markers for renal tumors derived from gene expression profiling studies using cDNA microarrays. Am J Surg Pathol. 27:199–205. 2003. View Article : Google Scholar
26	Bullard RS, Gibson W, Bose SK, et al: Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer. Mol Immunol. 45:839–848. 2008. View Article : Google Scholar : PubMed/NCBI
27	Joly S, Compton LM, Pujol C, Kurago ZB and Guthmiller JM: Loss of human beta-defensin 1, 2, and 3 expression in oral squamous cell carcinoma. Oral Microbiol Immunol. 24:353–360. 2009. View Article : Google Scholar : PubMed/NCBI
28	Yoshimoto T, Yamaai T, Mizukawa N, et al: Different expression patterns of beta-defensins in human squamous cell carcinomas. Anticancer Res. 23:4629–4633. 2003.PubMed/NCBI
29	Shuyi Y, Feng W, Jing T, et al: Human beta-defensin-3 (hBD-3) upregulated by LPS via epidermal growth factor receptor (EGFR) signaling pathways to enhance lymphatic invasion of oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 112:616–625. 2011. View Article : Google Scholar
30	Xu N, Wang YS, Pan WB, et al: Human alpha-defensin-1 inhibits growth of human lung adenocarcinoma xenograft in nude mice. Mol Cancer Ther. 7:1588–1597. 2008. View Article : Google Scholar : PubMed/NCBI
31	Toh Y, Oki E, Oda S, et al: Overexpression of the MTA1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis. Int J Cancer. 74:459–463. 1997. View Article : Google Scholar : PubMed/NCBI
32	Martin MD, Fischbach K, Osborne CK, Mohsin SK, Allred DC and O’Connell P: Loss of heterozygosity events impeding breast cancer metastasis contain the MTA1 gene. Cancer Res. 61:3578–3580. 2001.PubMed/NCBI
33	Hamatsu T, Rikimaru T, Yamashita Y, et al: The role of MTA1 gene expression in human hepatocellular carcinoma. Oncol Rep. 10:599–604. 2003.PubMed/NCBI
34	Sasaki H, Moriyama S, Nakashima Y, et al: Expression of the MTA1 mRNA in advanced lung cancer. Lung Cancer. 35:149–154. 2002. View Article : Google Scholar : PubMed/NCBI
35	Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A and Reinberg D: Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 13:1924–1935. 1999. View Article : Google Scholar : PubMed/NCBI
36	Toh Y and Nicolson GL: The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis. 26:215–227. 2009. View Article : Google Scholar : PubMed/NCBI
37	Ji Y, Zhang P, Lu Y and Ma D: Expression of MTA2 gene in ovarian epithelial cancer and its clinical implication. J Huazhong Univ Sci Technolog Med Sci. 26:359–362. 2006. View Article : Google Scholar : PubMed/NCBI
38	Lee H, Ryu SH, Hong SS, et al: Overexpression of metastasis-associated protein 2 is associated with hepatocellular carcinoma size and differentiation. J Gastroenterol Hepatol. 24:1445–1450. 2009. View Article : Google Scholar : PubMed/NCBI
39	Liu SL, Han Y, Zhang Y, et al: Expression of metastasis-associated protein 2 (MTA2) might predict proliferation in non-small cell lung cancer. Target Oncol. 7:135–143. 2012. View Article : Google Scholar : PubMed/NCBI
40	Covington KR, Brusco L, Barone I, et al: Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer. Breast Cancer Res Treat. 141:375–384. 2013. View Article : Google Scholar
41	Zhou C, Ji J, Cai Q, et al: MTA2 promotes gastric cancer cells invasion and is transcriptionally regulated by Sp1. Mol Cancer. 12:1022013. View Article : Google Scholar : PubMed/NCBI
42	Cui Y, Niu A, Pestell R, et al: Metastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cells. Mol Endocrinol. 20:2020–2035. 2006. View Article : Google Scholar
43	Luo J, Su F, Chen D, Shiloh A and Gu W: Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature. 408:377–381. 2000. View Article : Google Scholar : PubMed/NCBI